Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Protein-protein interaction network-based therapeutics discovery in a yeast model of Alzheimer's disease

FY 2012-13

Summary
Alzheimer's disease (AD) is a degenerative neuronal disease with increasing prevalence in the population. Although the aggregation of a few proteins has been implicated in the disease, AD's exact mechanism of emergence remains elusive and no therapies exist to stop or reverse the loss of neurons. Using a yeast model of Alzheimer's disease developed in our laboratory, we will screen thousands of chemicals to determine compounds that reduce toxicity in AD yeasts. The effective compounds will then be used to uncover which protein interactions have been altered in yeasts alleviated of toxicity. This discovery-based approach will lead to a list of compounds which could be further studied as potential therapeutics, while at the same time identifying protein interactions which could shed light on the cellular mechanism(s) underlying AD.
Program
CIHR Fellowship
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
282165
Name
Ehsani Sepehr
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Protein-protein interaction network-based therapeutics discovery in a yeast model of Alzheimer's disease
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Alzheimer'S Disease; Bioinformatics; High-Throughput Screening; Interactome Network; Ips Cells; Neurodegeneration; Protein Aggregation; Protein-Protein Interaction; Saccharomyces Cerevisiae; Yeast Two-Hybrid
Abstract
Alzheimer's disease (AD) is a degenerative neuronal disease with increasing prevalence in the population. Although the aggregation of a few proteins has been implicated in the disease, AD's exact mechanism of emergence remains elusive and no therapies exist to stop or reverse the loss of neurons. Using a yeast model of Alzheimer's disease developed in our laboratory, we will screen thousands of chemicals to determine compounds that reduce toxicity in AD yeasts. The effective compounds will then be used to uncover which protein interactions have been altered in yeasts alleviated of toxicity. This discovery-based approach will lead to a list of compounds which could be further studied as potential therapeutics, while at the same time identifying protein interactions which could shed light on the cellular mechanism(s) underlying AD.
Competitiondate
201302
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ehsani, Sepehr
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
Direct Payment - $150,000 Grant (2012-13) | Canada Spends